Cardiovascular and renal protection in type 2 diabetes mellitus: The role of calcium channel blockers

Journal of the American Society of Nephrology

Volumn 13, Issue SUPPL. 3, 2002, Pages

  Nosadini, Romano ^a   Tonolo, Giancarlo ^a  

^a Clinica Medica   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CILAZAPRIL; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; FOSINOPRIL; INDAPAMIDE; IRBESARTAN; ISRADIPINE; LISINOPRIL; LOSARTAN; NIFEDIPINE; NISOLDIPINE; PERINDOPRIL; RAMIPRIL; VERAPAMIL;

BLOOD PRESSURE REGULATION; CALCIUM TRANSPORT; CELL PROTECTION; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DIURESIS; DRUG CHOICE; DRUG MECHANISM; GLOMERULUS FILTRATION; GLUCOSE BLOOD LEVEL; HEART PROTECTION; HUMAN; HYPERTENSION; INHIBITION KINETICS; KIDNEY FUNCTION; KIDNEY INJURY; MECHANICAL STRESS; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATION; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; STROKE; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

EID: 0036840512     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. The Sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Intern Med 157: 2413-2446, 1997
2. Adler A, Stratton I, Neilo A, Yudkin J, Matthews D, Cull C, Wright A, Turner R, Holman R on behalf of the UK Prospective Diabetes Study Group: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS) prospective observational study. Br Med J 321: 412-419, 2000
3. 1999 World Health Organisation and International Society of Hypertension. Guidelines for the Management of Hypertension. J Hypertens 17: 151-183, 1999
4. Vasan R, Larson M, Leip E, Evans J, O'Donnel C, Kannel W, Levy D: Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 345: 1291-1297, 2001
5. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J: Blood pressure and end-stage renal disease in men. N Engl J Med 334: 13-18, 1996
6. Heart Outcomes Prevention Evaluation (HOPE) study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253-259, 2000
7. Lidholm L Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S; The LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes mellitus in the Losartan Intervention for end point reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359: 1004-1010, 2002
8. Hansson L, Zanchetti A, Carruthers S, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment randomized trial. Lancet 351: 1755-1762, 1998
9. Lewis E, Huinsiker L, Clarke W, Berl T, Pohl H, Lewis J, Ritz E, Atkins R, Rohde R, Raz L: Renoprotective effect of the angiotensin-receptor irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 251-262, 2001
10. Hansson L, Lindholm L, Ekbom T, Dahlof B, Lanke J, Schersten B, Wester PO, Hedner T. de Faire U: Randomized trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354: 1751-1744, 1999
11. Jensen T: The HOPE study and diabetes. Lancet 355: 1181, 2000
12. Taylor R: How large studies may mislead: The HOPE study. Practical Diabetes Int 18: 208-211, 2001
13. Lewis E, Huinsiker L, Bain R, Rohde R: The effects of angiotensin converting enzyme inhuition on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993
14. Brenner B, Cooper M, De Zeeuw D, Keane W, Mitch W, Parving H, Remuzzi G, Snapiun S, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-874, 2001
15. Estacio RO, Jeffers BW, Hiatt WH, Biggerstaff SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non insulin dependent diabetes and hypertension. N Engl J Med 338: 645-652, 1998
16. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F: Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trials in patients with hypertension and NIDDM. Diabetes Care 21: 597-603, 1998
17. Pahor M, Psaty B, Alderman M, Applegate W, William J, Cavazzini C, Furberg C: Health outcomes associated with calcium channel antagonists compared with other first line antihypertensive therapies a meta-analysis of randomized controlled trials. Lancet 356: 1949-1954, 2000
18. Blood Pressure Lowering Treatment Trialist's Collaboration: Effects of ACE inhibitors. Calcium antagonists and other blood pressure lowering drugs: Results of prospectively designed overviews of randomized trials. Lancet 356: 1955-1964, 2000
19. Opie L: Calcium channel blockers in hypertension: Reappraisal after new trials and major metanalyses. Am J Hypertens 14: 1074-1081, 2001
20. Avanzini F, Tognoni G, Insight and Nordil International Nifedipine GITS Study: Intervention as a goal in Hypertension Treatment. Nordic Diltiazem study. Lancet 356: 1927-1028, 2000
21. Zanchetti A, Rosei E, Dal Palù C, Leonetti C, Magnani B, Pessina A: The verapamil in hypertension and atherosclerosis study (VHAS): Results of long term randomized treatment with either verapamil or chlortalidone on carotid intima media thickness. J Hypertens 16: 1667-1676, 1998
22. Pitt B, Byington R, Furberg C, Hunninghake D, Mancini J, Miller M, Riley W: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 102: 1503-1510, 2000
23. Progress Collabortive Group: Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 358: 1033-1041, 2001
24. Taguma Y, Kitamoto Y, Futaki G, Ueda H, Monma H, Ishizaki M, Takahashi H, Sekino H, Sasaki Y: Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med. 26: 1617-1620, 1985
25. Chan JC, Cockram C, Nicholls M, Cheung CK, Swaminathan R: Comparison of enalapril and nifedipine in treating non insulin dependent diabetes associated with hypertension: One year analysis. Br Med J 305: 981-985, 1992
26. Bakris G, Copley J, Vicknair N, Sadler R, Leurgans S: Calcium channel blockers versus other anihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50: 1641-1650, 1996
27. Velussi M, Brocco E, Frigato F, Zolli M, Muollo B, Maioli M, Carraro A, Tonolo G, Fresu P, Cernigoi AM, Fioretto P, Nosadini R: Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 45: 216-222, 1996
28. Tryggvason K, Wartiovaara J: Molecular basis of glomerular permselectivity. Curr Opin Nephrol Hypertens 10: 543-549, 2001
29. Bonnet F, Cooper M, Kawachi H, Allen TJ, Boner G, Cao Z: Irbesartan normalizes the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 44: 874-77, 2001
30. Dzau VJ: Theodore Cooper Lecture: Tissue angiotensin and pathology of vascular disease: A unifying hypothesis. Hypertension 37: 1047-1052, 2001
31. Binder CJ, Weiher H, Exner M, Kerjaschki D: Glomerular over-production of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot processes flattening and proteinuria: A model of steroid resistant nephrosis sensitive to radical scavenger therapy. Am J Pathol 154: 1067-1075, 1999
32. American Diabetes Association: Clinical practice recommendations. Treatment of hypertension in adults with diabetes mellitus. Diabetes Care 25: S71-S73, 2002